About 15-hydroxyprostaglandin dehydrogenase [NAD(+)]
15-hydroxyprostaglandin dehydrogenase [NAD(+)] (HPGD) is a protein
from Homo sapiens identified by UniProt accession
P15428, 266 residues long.
MolForge cross-references it against 0 known binders and
283 disease associations.
Target properties
| Protein name | 15-hydroxyprostaglandin dehydrogenase [NAD(+)] |
|---|
| UniProt accession | P15428 |
|---|
| Gene | HPGD |
|---|
| Organism | Homo sapiens |
|---|
| Length | 266 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (283)
Diseases linked to this target (Open Targets).
- hypertrophic osteoarthropathy, primary, autosomal recessive, 1 · score 0.73
- cranio-osteoarthropathy · score 0.68
- isolated congenital digital clubbing · score 0.65
- Pachydermoperiostosis · score 0.50
- polyp of large intestine · score 0.34
- colorectal cancer · score 0.34
- eosinophil percentage of leukocytes · score 0.28
- eosinophil count · score 0.26
- abortion · score 0.20
- genetic disorder · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P15428-F1 | alphafold | PREDICTED | 96.91 | — |
Amino-acid sequence (266 residues)
MHVNGKVALV TGAAQGIGRA FAEALLLKGA KVALVDWNLE AGVQCKAALD EQFEPQKTLF IQCDVADQQQ LRDTFRKVVD HFGRLDILVN NAGVNNEKNW EKTLQINLVS VISGTYLGLD YMSKQNGGEG GIIINMSSLA GLMPVAQQPV YCASKHGIVG FTRSAALAAN LMNSGVRLNA ICPGFVNTAI LESIEKEENM GQYIEYKDHI KDMIKYYGIL DPPLIANGLI TLIEDDALNG AIMKITTSKG IHFQDYDTTP FQAKTQ
Explore 15-hydroxyprostaglandin dehydrogenase [NAD(+)] with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets